MDLinxPCOS is Now PMOS: Why the Name Change Matters for Diagnosis, Counseling, and Long-Term Care

🎓 Expert Commentary / Peer Perspective

A 14-year international consensus effort has renamed PCOS to PMOS, reflecting the syndrome’s systemic hormonal and metabolic scope. Diagnostic criteria are unchanged; clinical framing and patient counseling are the immediate practice implications.

Professional Impact

• The new name encodes three dimensions the old term obscured: polyendocrine dysfunction, metabolic risk, and ovarian involvement without centering it exclusively
• Persistent underdiagnosis has been partly attributed to narrow framing; the syndrome affects an estimated 1 in 8 women globally, many unidentified for years
• Patients frequently hold two opposing misconceptions: that normal ovarian imaging rules out the diagnosis, or that incidental cysts confirm it
• Full incorporation into international guidelines is expected by 2028, giving clinicians a transition window to update patient-facing language now

Action Items

• Update patient counseling to clarify that ovarian cysts are neither required nor sufficient for diagnosis
• Screen broadly for metabolic and cardiovascular comorbidities, not reproductive symptoms alone
• Address mental health (depression, anxiety) alongside endocrine and dermatologic manifestations
• Frame PMOS as a chronic multisystem endocrine disorder when setting long-term care expectations